Overview

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Status:
Withdrawn
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This research study is a pilot study to evaluate a new contrast agent, ferumoxytol, for the purpose of imaging lymph node metastases in patients with soft tissue sarcoma. This contrast agent is an investigational drug. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved ferumoxytol for this use. This drug has been used to image adults with other forms of cancer, however, it has only been used to image a small number of pediatric patients. Ferumoxytol has never been used to image sarcoma.
Phase:
N/A
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Treatments:
Ferrosoferric Oxide